Early Communications About Ongoing Safety Reviews
This is a discussion on Early Communications About Ongoing Safety Reviews within the FDA News forum, part of the Industry News and Updates category; Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
06-12-2009, 06:59 PM
|
|||
|
|||
Early Communications About Ongoing Safety Reviews
Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA issues an Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix) | industry_news | FDA News | 0 | 01-26-2009 01:09 PM |
| FDA updates the Early Communication about the Ongoing Safety Review of Bisphosphonates | industry_news | FDA News | 0 | 11-12-2008 11:48 AM |
| Epoetin alfa - Early Communication about an Ongoing Safety Review | industry_news | FDA News | 0 | 09-26-2008 12:42 PM |
| FDA issues an Early Communication About an Ongoing Safety Review of Vytorin, Zocor, and Zetia. | industry_news | FDA News | 0 | 08-22-2008 03:44 PM |
| FDA issues an Early Communication about an Ongoing Safety Review for Botox | industry_news | FDA News | 0 | 02-26-2008 03:30 PM |
© 2008 DrugManagementForum™ powered by |
 |